Jazz Pharmaceuticals plc — Director's Dealing 2022

Jul 7, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2022-07-05

Reporting Person: Tovey Christopher J. (EVP, COO & Managing Director E)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-07-05	Ordinary Shares	M	4032	$0.02	Acquired	19872	Direct
2022-07-05	Ordinary Shares	S	4032	$160.0	Disposed	15840	Direct
2022-07-05	Ordinary Shares	S	1177	$160.0	Disposed	14663	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-07-05	Non-Qualified Stock Option (right to buy)	$0.02	M	4032	Disposed	2031-02-22	Ordinary Shares (4032)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: Option to acquire Jazz Ordinary Shares received upon conversion of options to acquire shares of GW Pharmaceuticals PLC ("GW") pursuant to the GW Transaction Agreement among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW dated February 3, 2021 (the "Merger"). The effective date of the Merger was May 5, 2021. Fifty percent of the award will vest and be available for exercise on February 22, 2022 and fifty percent will vest and be available for exercise on February 22, 2023 in accordance with the terms of the Merger.